stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Free cash flow
Zai Lab Limited Unsponsored ADR's free cash flow for fiscal 2025 was −$164.1M, compared with −$276.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$196.9M. Over the past ten years it has ranged from −$568.2M (fiscal 2021) to −$12.2M (fiscal 2015); the current reading is higher than 64% of that period. Zai Lab Limited Unsponsored ADR ranks 539th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$164.1M | — |
| FY2024 | −$276.4M | — |
| FY2023 | −$192.7M | — |
| FY2022 | −$392.6M | — |
| FY2021 | −$568.2M | — |
| FY2020 | −$226.7M | — |
| FY2019 | −$206.3M | — |
| FY2018 | −$107.7M | — |
| FY2017 | −$41.4M | — |
| FY2016 | −$34.4M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$70.5M | — |
| Jun 2026 | −$64.8M | — |
| Mar 2026 | −$34.2M | — |
| Dec 2025 | −$27.3M | — |
| 30 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.5M |
| MBX MBX Biosciences, Inc. compare | −$85.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.9M |
| PHVS Pharvaris N.V. compare | −$178.1M |
| ZLAB Zai Lab Limited Unsponsored ADR | −$196.9M |
| XNCR Xencor, Inc. compare | −$208.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$242.1M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$314.5M |
| RCUS Arcus Biosciences, Inc. compare | −$465.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement